The trial compared ciltacabtagene autoleucel with standard of care in patients with MM who were refractory to lenalidomide. The researchers used a 3+3 study design to determine the maximum tolerated dose of CC-486 plus venetoclax. SAR’579 targets CD123 and co-engages NKp46 and CD16a on natural killer cells. Dr. Nabhan, who hosts The HemOnc Pulse, discusses the podcast and what he hopes listeners gain from it at ASCO 2023. Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial. Dr. Nabhan also speaks about his next book, which is expected to be released in fall 2024. The retrospective review was conducted by abstracting data from the medical charts of patients with Burkitt lymphoma. Moga-CHOP-14 significantly improved PFS in elderly patients with aggressive ATL who were not candidates for allogeneic HSCT. Less than half of patients had “clinically significant” CMV reactivation that required antiviral therapy. With four years of follow-up data, the best complete response rate was 58%. The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib. The study included patients who underwent an evaluation for allogeneic HSCT at a large academic medical center. The median time to achieving the first spleen volume reduction of at least 35% from baseline was 12 weeks. Jennifer Woyach, MD and colleagues presented the study's results during the 2023 ASCO Annual Meeting. Most patients (82%) had a low transfusion burden at baseline. Dr. Dickinson and colleagues presented the research at the 2023 American Society of Clinical Oncology Annual Meeting. A subset of TP53-mutated myeloid neoplasms, such as MDS, are preceded by TP53-mutated CCUS. Nearly one-third (29%) of patients were upstaged from their IPSS-R score by the IPSS-M. Dr. Garcia-Manero presented information about a phase Ib study of IRAK1/4 inhibition at the 2023 ASCO Annual Meeting. Pola-R-CHP and R-CHOP “demonstrated similar safety profiles” in older adults with previously untreated DLBCL.